WiseDiag, a technology company, has recently completed a financing round of 65 million yuan. This round was jointly led by Hangzhou Qianyu Zhihui and Wuxi Yuanqi, with participation from institutions including Zhejiang Fuhua Ruiyin, Shanghai Junhaoyun, and Jiaxing Qingyulan Xinjuneng. Among the investors, Ms. Kong Xiaoxian was one of the lead participants. Ms. Kong, who serves as the Chairperson and Dean of the Zhejiang Turing Computing Power Research Institute, invested in BrainCo. in 2015, becoming an angel investor for the company. In a recent interview, she emphasized that "the essence of investment lies in recognizing talent," noting that the vision and resilience of key personnel are often critical to the success of projects, whether in technology development or business operations. Her involvement has also brought attention to AI computing power and cutting-edge technology ecosystem resources for WiseDiag. The funds raised in this round will be primarily used to enhance the capabilities of the WiseDiag medical multimodal large model, drive user growth and commercialization for the Haoban AI platform, advance the WiseClaw medical Agent OS ecosystem, and deepen enterprise-level scenario solutions.

Since its establishment in 2023, WiseDiag has focused on the research and development of large AI models for healthcare, forming a model foundation, platform system, and user entry point around WiseDiag, WiseClaw, and Haoban AI. WiseDiag, as the company's self-developed medical multimodal large model, serves as the core foundation of its medical AI technology system. This model supports the understanding of various types of medical data and continues to evolve in areas such as medical report interpretation, health risk assessment, chronic disease management, and medical reasoning. As healthcare AI transitions from technological exploration to real-world applications, the company plans to further enhance WiseDiag's capabilities in medical multimodal understanding, health knowledge reasoning, and personalized health management, providing more robust technical support for personal health services and healthcare industry applications.

Building on WiseDiag, the company is simultaneously advancing health services for individual users and scenario empowerment for enterprise clients. For individual users, Haoban AI aims to create a more natural, professional, and user-friendly AI health service entry point, addressing needs such as medical report interpretation, health consultations, risk alerts, and health recommendations. The company is also exploring service conversion paths in more health consumption scenarios through integrated online and offline product forms, such as medical report interpretation cards. For industry clients, WiseClaw, developed as a medical Agent OS platform, transforms WiseDiag into configurable and combinable service modules through an "Agent + Skill" approach. Enterprises can build various types of agents, such as those for medical report interpretation, risk assessment, and chronic disease management, tailored to their business processes and integrated into existing systems to achieve the fusion of AI with real-world business workflows.

Currently, the company is actively pursuing collaboration discussions across scenarios including medical hardware, insurance services, hospitals, pharmaceuticals and health, retail pharmacies, and financial services. Following this funding round, WiseDiag will continue to advance model research and product system development: enhancing the professional capabilities of healthcare AI through WiseDiag, promoting the implementation of the Agent OS in industrial scenarios via WiseClaw, and strengthening health services for individual users with Haoban AI. Moving forward, the company will continue to leverage its large model capabilities and product systems to drive healthcare AI from capability validation to business application, providing more professional, stable, and implementable AI support for both individual users and enterprise clients.